Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain : A Prospective, Randomized, Phase 3 Trial - PubMed
6 hours ago
- #Pegfilgrastim
- #Chemotherapy
- #Bone Pain
- Pegfilgrastim-induced bone pain (PIBP) is common and lacks effective treatment.
- A randomized controlled trial was conducted to determine the association between the timing of pegfilgrastim administration and PIBP.
- Patients with stage I to III breast cancer naive to chemotherapy were allocated to 24-hour, 48-hour, or 72-hour pegfilgrastim administration postchemotherapy.
- The primary endpoint was the area under the curve (AUC) of daily worst bone pain scores over 5 days in the first chemotherapy cycle.
- The 72-hour group showed a significant reduction in mean AUC (6.05) compared to the 24-hour (12.74) and 48-hour (14.20) groups (P < 0.001).
- Incidence of severe bone pain (>5 on NRS) declined from 58.5% (24-hour) and 66.0% (48-hour) to 22.6% (72-hour) (P < 0.001).
- No significant difference in neutropenia incidence among groups, and no cases of febrile neutropenia (FN) were reported.
- Limitations include open-label design, single-center study, and relatively small sample size.
- Conclusion: Pegfilgrastim administration at 72 hours postchemotherapy reduces PIBP without increasing neutropenia or FN rates.